email article
While the Alzheimer s field waits for the FDA s decision on the investigational treatment aducanumab, drug developer Biogen has provided details and endpoints of EMBARK, the drug s ongoing phase IIIb redosing study.
Aducanumab, a monoclonal antibody that selectively binds to aggregated forms of amyloid beta, has raised considerable controversy in the wake of findings from two identical phase III studies, EMERGE and ENGAGE. The trials were terminated in March 2019 when a futility analysis determined aducanumab was unlikely to outperform placebo at completion. In October 2019, Biogen reversed its position, saying a review of previously unavailable data showed the drug actually reduced cognitive decline in EMERGE, but not in ENGAGE.
Global Dementia Drugs Market Expected to Exceed $19.6 Billion In 2026
- FinancialNewsMedia.com News Commentary
PALM BEACH, Fla., April 20, 2021 /PRNewswire/ While this past year living in quarantine during the pandemic did not just create economical damage, and social disruption… it could have also increased new cases of secondary medical results from the pandemic. According to various reports the outbreak of the COVID-19 pandemic is expected to have a significant impact on the Dementia drugs market. According to a research study by Katya Numbers et al., published in Nature Reviews Neurology, in January 2021, the population with dementia are at high risk of contracting COVID-19 infection as the cognitive symptoms cause difficulty to abide by the safety guidelines that were proposed to contain the viral spread. Furthermore, older populations with dementia are also more likely to have more severe disease consequences than those without dementia. Additionally, the statement from
Eisai Presents Breadth of Data Across Neurology Portfolio, Including Alzheimer s Disease, Insomnia and Epilepsy
Twenty-one presentations featuring data and information on investigational lecanemab in early Alzheimer s disease, DAYVIGO® (lemborexant) CIV in insomnia, FYCOMPA® (perampanel) CIII in epilepsy and investigational lorcaserin in Dravet Syndrome
News provided by
Share this article
Share this article
WOODCLIFF LAKE, N.J., April 16, 2021 /PRNewswire/ Eisai Inc., the U.S. pharmaceutical subsidiary of Eisai Co., Ltd., announced today that data from the company s deep neurology pipeline and portfolio, including Alzheimer s disease, insomnia and epilepsy, will be presented at the 73
rd Annual Meeting of the American Academy of Neurology (AAN), taking place virtually from April 17-22, 2021.
Biogen Inc : Biogen to Present Trial Design of Aducanumab EMBARK Re-Dosing Study in Poster Session at 2021 Virtual AAN Annual Meeting on April 17-22, 2021 finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.